Xbrane Biopharma AB
STO:XBRANE

Watchlist Manager
Xbrane Biopharma AB Logo
Xbrane Biopharma AB
STO:XBRANE
Watchlist
Price: 11.468 SEK -1.95% Market Closed
Market Cap: 236.4m SEK

Wall Street
Price Targets

XBRANE Price Targets Summary
Xbrane Biopharma AB

Wall Street analysts forecast XBRANE stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for XBRANE is 63.75 SEK with a low forecast of 63.125 SEK and a high forecast of 65.625 SEK.

Lowest
Price Target
63.125 SEK
450% Upside
Average
Price Target
63.75 SEK
456% Upside
Highest
Price Target
65.625 SEK
472% Upside
Xbrane Biopharma AB Competitors:
Price Targets
SBTX
SkinBioTherapeutics PLC
53% Upside
ADMA
ADMA Biologics Inc
51% Upside
RCKT
Rocket Pharmaceuticals Inc
116% Upside
EVAX
Evaxion Biotech A/S
176% Upside
NGNE
Neurogene Inc
243% Upside
PRAX
Praxis Precision Medicines Inc
49% Upside
IPH
Innate Pharma SA
317% Upside
SOBI
Swedish Orphan Biovitrum AB (publ)
12% Upside

Revenue
Forecast

Revenue Estimate
Xbrane Biopharma AB

For the last 11 years the compound annual growth rate for Xbrane Biopharma AB's revenue is 88%. The projected CAGR for the next 3 years is 38%.

88%
Past Growth
38%
Estimated Growth
Estimates Accuracy
-19%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Xbrane Biopharma AB

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
5%
Average Beat

Net Income
Forecast

Net Income Estimate
Xbrane Biopharma AB

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-91%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is XBRANE's stock price target?
Price Target
63.75 SEK

According to Wall Street analysts, the average 1-year price target for XBRANE is 63.75 SEK with a low forecast of 63.125 SEK and a high forecast of 65.625 SEK.

What is Xbrane Biopharma AB's Revenue forecast?
Projected CAGR
38%

For the last 11 years the compound annual growth rate for Xbrane Biopharma AB's revenue is 88%. The projected CAGR for the next 3 years is 38%.

Back to Top